@KathleenCoreyMD @MGHMedicine #NAFLD prevalence high in the #MENA region with a predicted rise over time @CLDFoundation #liverconnect2022
December 3, 2024 at 2:14 AM
@KathleenCoreyMD @MGHMedicine #NAFLD prevalence high in the #MENA region with a predicted rise over time @CLDFoundation #liverconnect2022
@AlkhouriNaim @LiverArizona #NAFLD prevalence very high in Latin America. Contributors include #PNLAP3 genetics, diet and other metabolic factors @CLDFoundation #liverconnect2022
December 3, 2024 at 2:14 AM
@AlkhouriNaim @LiverArizona #NAFLD prevalence very high in Latin America. Contributors include #PNLAP3 genetics, diet and other metabolic factors @CLDFoundation #liverconnect2022
@AlkhouriNaim @LiverArizona some common sense public policies to address #NAFLD which apply to Latin America and probably anywhere @CLDFoundation #liverconnect2022
December 3, 2024 at 2:14 AM
@AlkhouriNaim @LiverArizona some common sense public policies to address #NAFLD which apply to Latin America and probably anywhere @CLDFoundation #liverconnect2022
@ZobairYounossi NAFLD vs. MAFLD name change needs to have a purpose or contribute to advancement in the field or else might cause needless confusion. @AASLDtweets convening meeting to discuss name change in July @CLDFoundation #liverconnect2022
December 3, 2024 at 2:14 AM
@ZobairYounossi NAFLD vs. MAFLD name change needs to have a purpose or contribute to advancement in the field or else might cause needless confusion. @AASLDtweets convening meeting to discuss name change in July @CLDFoundation #liverconnect2022
Dr. Cusi it’s a two way street. #NAFLDf="/hashtag/NAFLD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#NAFLD increases by 2-fold the risk of incident diabetes. Do HbA1c on all #NAFLD patients @CLDFoundation #liverconnect2022
December 3, 2024 at 2:14 AM
Dr. Cusi it’s a two way street. #NAFLDf="/hashtag/NAFLD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#NAFLD increases by 2-fold the risk of incident diabetes. Do HbA1c on all #NAFLD patients @CLDFoundation #liverconnect2022
Dr. Cusi: common sense @AmerGastroAssn endorsed algorithm for #NAFLD treatment emphasises NITs @CLDFoundation #liverconnect2022
December 3, 2024 at 2:14 AM
Dr. Cusi: common sense @AmerGastroAssn endorsed algorithm for #NAFLD treatment emphasises NITs @CLDFoundation #liverconnect2022
@KanwalFasiha low socioeconomic status=more #NAFLD and worse outcome @CLDFoundation #liverconnect2022
December 3, 2024 at 2:14 AM
@KanwalFasiha low socioeconomic status=more #NAFLD and worse outcome @CLDFoundation #liverconnect2022
@KanwalFasiha As paradoxical as this sounds, food insecurity and obesity often coexist! Very important concept and commonly seen in #NAFLD patients @CLDFoundation #liverconnect2022
December 3, 2024 at 2:09 AM
@KanwalFasiha As paradoxical as this sounds, food insecurity and obesity often coexist! Very important concept and commonly seen in #NAFLD patients @CLDFoundation #liverconnect2022
@NoureddinMD @CedarsSinai common sense @AmerGastroAssn endorsed algorithm for #NAFLD risk stratification. My take: ok but my issue is that intermediate group will be very large because of limitation in test performance @CLDFoundation #liverconnect2022
December 3, 2024 at 2:09 AM
@NoureddinMD @CedarsSinai common sense @AmerGastroAssn endorsed algorithm for #NAFLD risk stratification. My take: ok but my issue is that intermediate group will be very large because of limitation in test performance @CLDFoundation #liverconnect2022
@NoureddinMD @CedarsSinai NITs seem to perform somewhat differently by ethnicity (but not by much) except for VCTE where PPV drops significantly in whites w/BMI >30 (but not Asians) and age <40 in general. This does mirror my experience. @CLDFoundation #liverconnect2022
December 3, 2024 at 2:09 AM
@NoureddinMD @CedarsSinai NITs seem to perform somewhat differently by ethnicity (but not by much) except for VCTE where PPV drops significantly in whites w/BMI >30 (but not Asians) and age <40 in general. This does mirror my experience. @CLDFoundation #liverconnect2022
@DrLoomba @UCSDHealth CAP cutoff for steatosis seems to vary in US vs Asia. It’s also only about 80% accurate. Is this imprecision or a disparity? Or Technical issue related to data acquisition? I didn’t know this. @CLDFoundation #liverconnect2022
December 3, 2024 at 2:09 AM
@DrLoomba @UCSDHealth CAP cutoff for steatosis seems to vary in US vs Asia. It’s also only about 80% accurate. Is this imprecision or a disparity? Or Technical issue related to data acquisition? I didn’t know this. @CLDFoundation #liverconnect2022
@DrLoomba this slide again. Again, it’s all about the intermediates for me but as the slides highlights, if 100 mil Americans have #NAFLD, this would allow you to risk stratify 70 mil @CLDFoundation #liverconnect2022
December 3, 2024 at 2:09 AM
@DrLoomba this slide again. Again, it’s all about the intermediates for me but as the slides highlights, if 100 mil Americans have #NAFLD, this would allow you to risk stratify 70 mil @CLDFoundation #liverconnect2022
Dr. Steve Harrison @Pinnacle_TX access to proven treatments for #NASH eg: bariatric surgery clear discrepancy in access between whites vs. Non whites @CLDFoundation #liverconnect2022
December 3, 2024 at 2:09 AM
Dr. Steve Harrison @Pinnacle_TX access to proven treatments for #NASH eg: bariatric surgery clear discrepancy in access between whites vs. Non whites @CLDFoundation #liverconnect2022
Dr. Harrison @Pinnacle_TX PNPLA3 SNP probably plays some role in differences in disease progression and response to therapy. Should we be risk stratifying for it in trials? @CLDFoundation #liverconnect2022
December 3, 2024 at 2:09 AM
Dr. Harrison @Pinnacle_TX PNPLA3 SNP probably plays some role in differences in disease progression and response to therapy. Should we be risk stratifying for it in trials? @CLDFoundation #liverconnect2022
@DrLoomba @UCSD_GI natural history of #NAFLD important to discuss with patients to give perspective on timeline for risk modification @CLDFoundation #liverconnect2022
December 3, 2024 at 2:09 AM
@DrLoomba @UCSD_GI natural history of #NAFLD important to discuss with patients to give perspective on timeline for risk modification @CLDFoundation #liverconnect2022
@DrLoomba @UCSD_GI ELF now available in US and can be useful as a diagnostic and prognostic tool @CLDFoundation #liverconnect2022
December 3, 2024 at 2:08 AM
@DrLoomba @UCSD_GI ELF now available in US and can be useful as a diagnostic and prognostic tool @CLDFoundation #liverconnect2022
@ZobairYounossi @InovaHealth nice summary of the natural history of #NAFLD. Heart disease overall still main driver of mortality @CLDFoundation #liverconnect2022
December 3, 2024 at 2:08 AM
@ZobairYounossi @InovaHealth nice summary of the natural history of #NAFLD. Heart disease overall still main driver of mortality @CLDFoundation #liverconnect2022
Dr. Harrison @Pinnacle_TX summarizes #NAFLD Compounds in advanced stage clinical trials @CLDFoundation #liverconnect2022
December 3, 2024 at 2:03 AM
Dr. Harrison @Pinnacle_TX summarizes #NAFLD Compounds in advanced stage clinical trials @CLDFoundation #liverconnect2022